p53 gene mutations are rare in patients but common in patient-originating cell lines in multiple myeloma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Elevated serum p53 protein is linked to poor prognosis in multiple myeloma (MM).
• The relationship between serum p53 levels and p53 gene mutations in MM remains unclear.

Purpose of the Study:

• To investigate the presence of p53 gene mutations in multiple myeloma patients with detectable serum p53 protein.
• To determine if serum p53 protein levels correlate with p53 gene mutations in MM.
• To examine the occurrence of p53 mutations in MM cell lines.

Main Methods:

• Analysis of p53 gene mutations in 29 bone marrow samples from MM patients using polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) and direct sequencing.
• Detection of serum p53 protein concentrations.
• Genomic analysis of three established MM cell lines.

Main Results:

• No p53 gene mutations were detected in the bone marrow samples of MM patients, despite 41% exhibiting elevated serum p53 protein.
• All three analyzed MM cell lines harbored p53 mutations in exon 5.
• The original patient samples used to establish these cell lines did not show these p53 mutations.

Conclusions:

• Detectable serum p53 protein levels in multiple myeloma are not associated with p53 gene mutations at diagnosis.
• p53 gene mutations can emerge during in vitro culture of MM cells, suggesting they may arise during disease progression or treatment.
• Further research is needed to understand the role of p53 in MM pathogenesis and its potential as a prognostic marker.